HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi Adds Consumer Brands, Grows Footprint With Boehringer Ingelheim Deal

This article was originally published in The Tan Sheet & The Rose Sheet

Executive Summary

BI international brands including Mucoangin cough suppressant and Dulcolax constipation treatment and US heartburn remedy Zantac would join Sanofi's consumer portfolio including US brands Allegra Allergy antihistamines and Nasacort Allergy 24HR nasal decongestant in the firm's proposed asset swap.

You may also be interested in...



US OTC Switch For Cialis At Top Of To-Do List For Sanofi’s North American Consumer Health Chief

Andrew Loucks moves to Sanofi from helm of consumer health and technology firm Sensory Cloud as business navigates gaining US OTC heartburn market share for Zantac brand, which it relaunched with famotidine replacing ranitidine as the active ingredient.

Sanofi Looks To Climb Consumer Ladder In Boehringer Business Swap

A pending agreement includes a $5.2bn cash payment from Boehringer to Sanofi but excludes Boehringer’s consumer product business in China. The brands Sanofi will add to its consumer health lineup include two marketed in the US, Dulcolax constipation relief and Zantac heartburn remedy.

Sanofi Board Forces Out CEO Chris Viehbacher Amid Lantus Woes

Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

RS123158

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel